Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ximetinib
- Development stage
- Unknown
- Lead developer
- Shanghai Institute of Materia Medica
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Ximetinib (SIMM-1803) is an orally bioavailable, small-molecule multi-target tyrosine kinase inhibitor (TKI) developed by the Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences. It is designed to simultaneously inhibit several key pathways involved in tumor growth and maintenance, specifically targeting vascular endothelial growth factor receptor 2 (VEGFR2), fibroblast growth factor receptor 1 (FGFR1), and platelet-derived growth factor receptor beta (PDGFRβ). By blocking these receptors, ximetinib inhibits tumor-associated angiogenesis, fibroblast-mediated stromal support, and direct tumor cell proliferation. It is currently in early-phase clinical development for the treatment of advanced solid tumors, particularly those that are refractory to standard-of-care therapies.
- Other names
- ximetinib
02
Targets
KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on ximetinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ximetinib.